LBL-024 combo for advanced solid tumors (NSCLC)
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination for people with advanced non-small cell lung cancer or other solid tumors. It aims to see if adding LBL-024 to other treatments can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced solid tumors that are measurable on scans.
- You are willing to follow the study schedule and tests.
- You have adequate organ function (kidneys, liver, bone marrow).
- You are not pregnant, breastfeeding, or planning pregnancy during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
This trial tests a new combination drug called LBL-024 in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the treatment can help shrink the tumor or slow the cancer's growth.
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
Hear when a new Advanced Solid Tumour trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.